Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.61 |
| ▸ | KLRK1 | P26718 | 6/20 | 0.55 |
| ▸ | MICA | Q29983 | 6/20 | 0.55 |
| ▸ | RAET1L | Q5VY80 | 5/20 | 0.55 |
| ▸ | MTTP | P55157 | 7/20 | 0.52 |
| ▸ | APOB | P04114 | 5/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | CRHBP | P24387 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.49 |
| ▸ | ADAMTS7 | Q9UKP4 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13485786 | 0.86 | GAA (0.59) | GAAKLRK1MICARAET1LMTTP | |
| SCHEMBL14102364 | 0.86 | CDK4 (0.52) | GAAMTTPRAB9A | |
| SCHEMBL29971478 | 0.86 | CDK4 (0.52) | GAAMTTPRAB9A | |
| SCHEMBL20665433 | 0.84 | GAA (0.57) | GAAKLRK1MICARAET1LMTTP | |
| SCHEMBL18806401 | 0.83 | PDK2 (0.51) | GAANPC1RAB9AALDH1A1 | |
| SCHEMBL14205317 | 0.83 | GAA (0.60) | GAAKLRK1MICARAET1LMTTP | |
| SCHEMBL171542 | 0.82 | TRPV1 (0.54) | GAAKLRK1MICARAET1LMTTP | |
| SCHEMBL21590157 | 0.82 | SLC6A4 (0.66) | GAANPC1RAB9AKDM4EALDH1A1 | |
| SCHEMBL31393757 | 0.82 | CHRNB2 (0.71) | GAAMTTPAPOBNPC1RAB9A | |
| SCHEMBL3223294 | 0.81 | CHRNB2 (0.65) | GAAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6756384-B2 | TREATMENT OF DISEASES AND DISORDERS RELATED TO THE HISTAMINE H3 RECEPTOR. | NOVO NORDISK A/S (DK) | 2004-06-29 | — | — | US | disclosed |
| US-20030135056-A1 | Imidazole compounds | HIGH POINT PHARMACEUTICALS, LLC | 2003-07-17 | — | — | US | disclosed |
| EP-1268484-A1 | CONDENSED IMIDAZOLES AS HISTAMINE H3 RECEPTOR LIGANDS | NOVO NORDISK A/S (DK) | 2003-01-02 | — | — | EP | disclosed |
| US-6437147-B1 | FOR THERAPY OF DISEASES OF CENTRAL NERVOUS SYSTEM, PERIPHERAL NERVOUS SYSTEM, CARDIOVASCULAR SYSTEM, PULMONARY SYSTEM, GASTROINTESTINAL SYSTEM AND ENDOCRINOLOGICAL SYSTEM | NOVO NORDISK (DK) | 2002-08-20 | — | — | US | disclosed |
| US-20020058659-A1 | Imidazole compounds | HIGH POINT PHARMACEUTICALS, LLC | 2002-05-16 | — | — | US | disclosed |
| WO-2001068652-A1 | CONDENSED IMIDAZOLES AS HISTAMINE H3 RECEPTOR LIGANDS | NOVO NORDISK A/S (DK) | 2001-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030135056-A1 | Imidazole compounds | HRH3, HRH4, HRH2 | GAA 996/4885KLRK1 1094/4885MICA 1021/4885 |
| US-20020058659-A1 | Imidazole compounds | HRH3, HRH4, HRH2 | GAA 996/4885KLRK1 1094/4885MICA 1021/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.